Skip to main content
Premium Trial:

Request an Annual Quote

Gradalis Raises $24M in Series B

Premium

Gradalis announced this week that it has closed a $24 million Series B round of financing.

The money, the firm said, would be used to fund late-stage clinical development of its FANG cancer vaccine, and to ramp up manufacturing to accommodate the therapy's commercial launch. The funding will also be used to advance Gradalis' bi-functional shRNA drug candidates.

The FANG vaccine, which incorporates the shRNA technology, is currently in phase II testing in patients with ovarian cancer, advanced melanoma, and colorectal cancer. Gradalis also has a purely RNAi cancer drug in phase I.

A company official recently told Gene Silencing News that the firm is aiming to expand the use of its technology through partnerships (GSN 10/11/2012).

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.